Literature DB >> 10947203

Behavioural and emotional problems in early-treated adolescents with phenylketonuria in comparison with diabetic patients and healthy controls.

J Weglage1, M Grenzebach, M Pietsch, R Feldmann, R Linnenbank, J Denecke, H G Koch.   

Abstract

Even early-treated patients with phenylketonuria (PKU) have a higher risk of psychosocial maladjustment. This study was performed to determine whether emotional and behavioural problems are specific in phenylketonurics and whether they depend on the quality of biochemical control. This comparative study covered 42 PKU patients aged 10-18 years (mean 14.7 years) and 42 diabetic patients matched for sex, age and socioeconomic status. Patients' groups were compared with a control sample of healthy controls (n = 2900) from an epidemiological study. We used the Child Behavior Check List (CBCL) according to Achenbach, intelligence quotient (IQ) test according to Weiss, and monitoring of blood phenylalanine concentrations and HBA1 concentrations. Internalizing problems such as depressive mood, anxiety, physical complaints or social isolation were significantly elevated in both phenylketonuric and diabetic patients, whereas externalizing problems were not. The two patient groups did not differ significantly either in the degree or in the pattern of their psychological profile. In both groups no significant correlations could be computed between the psychological characteristics and the biochemical control, the IQ, and the socioeconomic status. No patient was undergoing psychiatric treatment or psychotherapy. Our results strongly support a psychological perspective for the development of behavioural and emotional problems in both phenylketonuric and diabetic patients. Thus, medical treatment should be accompanied by psychological support for the families.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947203     DOI: 10.1023/a:1005664231017

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

1.  Epidemiology and course of psychiatric disorders in school-age children--results of a longitudinal study.

Authors:  G Esser; M H Schmidt; W Woerner
Journal:  J Child Psychol Psychiatry       Date:  1990-01       Impact factor: 8.982

2.  Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria.

Authors:  J Weglage; K Ullrich; M Pietsch; B Fünders; F Güttler; E Harms
Journal:  Pediatr Res       Date:  1997-09       Impact factor: 3.756

3.  Psychosocial aspects in phenylketonuria.

Authors:  J Weglage; B Fünders; K Ullrich; A Rupp; E Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

4.  Psychiatric diagnosis and behavioral characteristics of phenylketonuric children.

Authors:  G M Realmuto; B D Garfinkel; M Tuchman; M Y Tsai; P N Chang; R O Fisch; S Shapiro
Journal:  J Nerv Ment Dis       Date:  1986-09       Impact factor: 2.254

5.  Psychological and social findings in adolescents with phenylketonuria.

Authors:  J Weglage; B Fünders; B Wilken; D Schubert; E Schmidt; P Burgard; K Ullrich
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

6.  Psychopathology of patients treated early for phenylketonuria: results of the German collaborative study of phenylketonuria.

Authors:  P Burgard; M Armbruster; E Schmidt; A Rupp
Journal:  Acta Paediatr Suppl       Date:  1994-12

7.  Behavioural deviance in children with early treated phenylketonuria.

Authors:  J E Stevenson; J Hawcroft; M Lobascher; I Smith; O H Wolff; P J Graham
Journal:  Arch Dis Child       Date:  1979-01       Impact factor: 3.791

8.  Phenylalanine control and family functioning in early-treated phenylketonuria.

Authors:  M Reber; A E Kazak; P Himmelberg
Journal:  J Dev Behav Pediatr       Date:  1987-12       Impact factor: 2.225

9.  Personality characteristics in patients with phenylketonuria treated early.

Authors:  J Weglage; A Rupp; E Schmidt
Journal:  Pediatr Res       Date:  1994-05       Impact factor: 3.756

10.  Dietary problems of phenylketonuria: effect on CNS transmitters and their possible role in behaviour and neuropsychological function.

Authors:  F Güttler; H Lou
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

View more
  21 in total

1.  Healthy coping: issues and implications in diabetes education and care.

Authors:  Dan Kent; Linda Haas; David Randal; Elizabeth Lin; Carolyn T Thorpe; Suzanne A Boren; Jan Fisher; Joan Heins; Patrick Lustman; Joe Nelson; Laurie Ruggiero; Tim Wysocki; Karen Fitzner; Dawn Sherr; Annette Lenzi Martin
Journal:  Popul Health Manag       Date:  2010-10       Impact factor: 2.459

2.  Developmental Trajectories of Executive and Verbal Processes in Children with Phenylketonuria.

Authors:  Zoë W Hawks; Michael J Strube; Neco X Johnson; Dorothy K Grange; Desirée A White
Journal:  Dev Neuropsychol       Date:  2018-02-12       Impact factor: 2.253

3.  The impact of galactosaemia on quality of life--a pilot study.

Authors:  C Lambert; A Boneh
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

4.  Family conditions and dietary control in phenylketonuria.

Authors:  G M Olsson; S M Montgomery; J Alm
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

5.  Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Authors:  Anna Hood; Jo Ann V Antenor-Dorsey; Jerrel Rutlin; Tamara Hershey; Joshua S Shimony; Robert C McKinstry; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desiree A White
Journal:  Mol Genet Metab       Date:  2014-11-13       Impact factor: 4.797

Review 6.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

7.  Association between emotional and behavioral problems and metabolic control in children and adolescents with Type 1 diabetes.

Authors:  S Akbaş; K Karabekiroğlu; T Ozgen; G Tasdemir; M Karakurt; A Senses; O Böke; M Aydin
Journal:  J Endocrinol Invest       Date:  2009-04       Impact factor: 4.256

8.  Convergent patterns of association between phenylalanine hydroxylase variants and schizophrenia in four independent samples.

Authors:  Michael E Talkowski; Lora McClain; Trina Allen; L Dianne Bradford; Monica Calkins; Neil Edwards; Lyudmila Georgieva; Rodney Go; Ruben Gur; Raquel Gur; George Kirov; Kodavali Chowdari; Joseph Kwentus; Paul Lyons; Hader Mansour; Joseph McEvoy; Michael C O'Donovan; Judith O'Jile; Michael J Owen; Alberto Santos; Robert Savage; Draga Toncheva; Gerard Vockley; Joel Wood; Bernie Devlin; Vishwajit L Nimgaonkar
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-06-05       Impact factor: 3.568

9.  Psychosocial issues in families affected by maple syrup urine disease.

Authors:  Wendy Packman; Shelly L Henderson; Indira Mehta; Rama Ronen; Dean Danner; Beth Chesterman; Seymour Packman
Journal:  J Genet Couns       Date:  2007-08-17       Impact factor: 2.537

Review 10.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.